Skip to main content

N,N-bis(Cyclohexanol)amine Aryl Esters: The Discovery of a New Class of Highly Potent Inhibitors of ransporter-Dependent Multidrug Resistance (MDR)

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

Multidrug resistance (MDR) is a kind of acquired resistance of microorganisms and cancer cells to chemotherapeutic drugs that are characterized by different chemical structure and different mechanism of action. Classic MDR is due to a lower intracellular concentration of cytotoxic drugs that is associated with accelerated efflux of the chemotherapeutic drugs and is the consequence of the over expression of transporter proteins that act as extrusion pumps. Pglycoprotein (P-gp/ABCB1) is the most important and studied member of such proteins belonging to the ATP Binding Cassette (ABC) superfamily of transporters that use ATP as energy source.

Inhibition of the functions of P-gp and other ABC proteins could represent a way to circumvent appearance of MDR in cancer cells and the most classical pharmacological strategy is the administration of agents able to modulate the P-gp function.

On the basis of the known characteristics of the recognition site of P-gp, we have designed a new class of P-gp-mediated MDR reverters. These compounds are flexible molecules carrying a basic nitrogen atom flanked, at properly modulated distance, by two aromatic moieties; most of them possess MDR inhibitory activity on anthracycline-resistant erytroleukemia K562 cells. By applying the frozen analog approach to that series of very flexible MDR reverters, we identified a new series of N,N-bis(cyclohexanol)amine aryl esters that show very interesting MDR-reversing properties. Among them, compound 15d, that consistently shows low nanomolar potency and high efficacy in all the tests used, appears as a new pharmacological tool for P-gp studies and a promising lead for the development of potent, efficient and safe MDR reverters.

Keywords: ABC Modulators; ATP Binding Cassette (ABC); Acridone carboxamides; Anthracycline-resistant erytroleukemia K562; Antiarrhythmic agents; Breast cancer-resistance protein; CYP3A4; Calmodulin antagonists; Chemosensitizers; Cyclosporin A; Dihydropyridines; Idarubicin activity; Immunomodulators; Ipophilicity; K562 cell line; K562/DOX cell line; MDR-reversing activity; Multidrug resistance reverters; N,N-bis(Alkanol)amine aryl esters; N,N-bis(Cyclohexanol)amine Aryl Esters; N,N-bis(Cyclohexanol)amine aryl esters; Negative Chronotropic Activity; Negative Inotropic Activity; Nucleotide binding domains (NBDs); P-gp expression; P-gp inhibitors; Pervilleine; Pglycoprotein; Phenoxazines; Pyridine analogues; QacR repressor protein; Quinidine; Quinine derivatives; Sav1866; Stipiamide homodimers; THPadriamycin; Transmembrane domains (TMDs); Transporter-Dependent Multidrug Resistance; Triazines; Tropane alkaloids; Vasodilatant Acti; Verapamil; Vinca alkaloid analogues

Document Type: Research Article

DOI: https://doi.org/10.2174/156802610792928031

Affiliations: Dipartimento di Scienze Farmaceutiche, Università di Firenze, Polo Scientifico. Via U. Schiff 6,50019 Sesto Fiorentino (FI), Italy.

Publication date: 2010-12-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more